Breast implant-associated anaplastic large-cell lymphoma in a transgender woman

Mintsje De Boer, Wouter B. Van Der Sluis, Jan P. De Boer, Lucy I.H. Overbeek, Flora E. Van Leeuwen, Hinne A. Rakhorst, René R.W.J. Van Der Hulst, Nathalie J. Hijmering, Mark Bram Bouman, Daphne De Jong

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare but serious complication in patients with breast implants, Patients are at risk of BIA-ALCL whether they receive breast implants for cosmetic reasons or for reconstructive purposes after surgery for breast cancer or prophylactic mastectomy. During the past decade, an increased number of reports have addressed BIA-ALCL. Herein, we describe BIA-ALCL in a transgender woman. The patient received breast implants as part of her gender transition and was diagnosed with BIA-ALCL 20 years later. The patient underwent several revisional operations in the 20 years after her primary breast surgery to treat unexplained pain with low-grade fever, severe capsular contracture (Baker grade III-IV), and several instances of implant rupture. In July 2016, the patient presented to our office with "late-onset" periprosthetic seroma 5 years after her last revisional breast surgery. She was diagnosed with BIA-ALCL without capsular invasion based on results of cytologic analysis of the periprosthetic seroma and histologic evaluation of the periprosthetic capsule. This diagnosis was verified further by results of immunohistochemical testing, which indicated expression of CD30 and T-cell markers in the periprosthetic seroma only. Our intentions with this case report are to demonstrate that all patients who undergo breast implantation, including transgender women, are at risk of BIA-ALCL and to highlight the importance of cytomorphologic and immunohistochemical screening of seroma fluid in patients with late-onset periprosthetic seroma.

Original languageEnglish
Pages (from-to)NP83-NP87
JournalAesthetic Surgery Journal
Volume37
Issue number8
DOIs
Publication statusPublished - 1 Sep 2017

Cite this

De Boer, Mintsje ; Van Der Sluis, Wouter B. ; De Boer, Jan P. ; Overbeek, Lucy I.H. ; Van Leeuwen, Flora E. ; Rakhorst, Hinne A. ; Van Der Hulst, René R.W.J. ; Hijmering, Nathalie J. ; Bouman, Mark Bram ; De Jong, Daphne. / Breast implant-associated anaplastic large-cell lymphoma in a transgender woman. In: Aesthetic Surgery Journal. 2017 ; Vol. 37, No. 8. pp. NP83-NP87.
@article{c9faba3cfa7e492a8c092248f6dbbf70,
title = "Breast implant-associated anaplastic large-cell lymphoma in a transgender woman",
abstract = "Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare but serious complication in patients with breast implants, Patients are at risk of BIA-ALCL whether they receive breast implants for cosmetic reasons or for reconstructive purposes after surgery for breast cancer or prophylactic mastectomy. During the past decade, an increased number of reports have addressed BIA-ALCL. Herein, we describe BIA-ALCL in a transgender woman. The patient received breast implants as part of her gender transition and was diagnosed with BIA-ALCL 20 years later. The patient underwent several revisional operations in the 20 years after her primary breast surgery to treat unexplained pain with low-grade fever, severe capsular contracture (Baker grade III-IV), and several instances of implant rupture. In July 2016, the patient presented to our office with {"}late-onset{"} periprosthetic seroma 5 years after her last revisional breast surgery. She was diagnosed with BIA-ALCL without capsular invasion based on results of cytologic analysis of the periprosthetic seroma and histologic evaluation of the periprosthetic capsule. This diagnosis was verified further by results of immunohistochemical testing, which indicated expression of CD30 and T-cell markers in the periprosthetic seroma only. Our intentions with this case report are to demonstrate that all patients who undergo breast implantation, including transgender women, are at risk of BIA-ALCL and to highlight the importance of cytomorphologic and immunohistochemical screening of seroma fluid in patients with late-onset periprosthetic seroma.",
author = "{De Boer}, Mintsje and {Van Der Sluis}, {Wouter B.} and {De Boer}, {Jan P.} and Overbeek, {Lucy I.H.} and {Van Leeuwen}, {Flora E.} and Rakhorst, {Hinne A.} and {Van Der Hulst}, {Ren{\'e} R.W.J.} and Hijmering, {Nathalie J.} and Bouman, {Mark Bram} and {De Jong}, Daphne",
year = "2017",
month = "9",
day = "1",
doi = "10.1093/asj/sjx098",
language = "English",
volume = "37",
pages = "NP83--NP87",
journal = "Aesthetic Surgery Journal",
issn = "1090-820X",
publisher = "SAGE Publications Inc.",
number = "8",

}

De Boer, M, Van Der Sluis, WB, De Boer, JP, Overbeek, LIH, Van Leeuwen, FE, Rakhorst, HA, Van Der Hulst, RRWJ, Hijmering, NJ, Bouman, MB & De Jong, D 2017, 'Breast implant-associated anaplastic large-cell lymphoma in a transgender woman' Aesthetic Surgery Journal, vol. 37, no. 8, pp. NP83-NP87. https://doi.org/10.1093/asj/sjx098

Breast implant-associated anaplastic large-cell lymphoma in a transgender woman. / De Boer, Mintsje; Van Der Sluis, Wouter B.; De Boer, Jan P.; Overbeek, Lucy I.H.; Van Leeuwen, Flora E.; Rakhorst, Hinne A.; Van Der Hulst, René R.W.J.; Hijmering, Nathalie J.; Bouman, Mark Bram; De Jong, Daphne.

In: Aesthetic Surgery Journal, Vol. 37, No. 8, 01.09.2017, p. NP83-NP87.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Breast implant-associated anaplastic large-cell lymphoma in a transgender woman

AU - De Boer, Mintsje

AU - Van Der Sluis, Wouter B.

AU - De Boer, Jan P.

AU - Overbeek, Lucy I.H.

AU - Van Leeuwen, Flora E.

AU - Rakhorst, Hinne A.

AU - Van Der Hulst, René R.W.J.

AU - Hijmering, Nathalie J.

AU - Bouman, Mark Bram

AU - De Jong, Daphne

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare but serious complication in patients with breast implants, Patients are at risk of BIA-ALCL whether they receive breast implants for cosmetic reasons or for reconstructive purposes after surgery for breast cancer or prophylactic mastectomy. During the past decade, an increased number of reports have addressed BIA-ALCL. Herein, we describe BIA-ALCL in a transgender woman. The patient received breast implants as part of her gender transition and was diagnosed with BIA-ALCL 20 years later. The patient underwent several revisional operations in the 20 years after her primary breast surgery to treat unexplained pain with low-grade fever, severe capsular contracture (Baker grade III-IV), and several instances of implant rupture. In July 2016, the patient presented to our office with "late-onset" periprosthetic seroma 5 years after her last revisional breast surgery. She was diagnosed with BIA-ALCL without capsular invasion based on results of cytologic analysis of the periprosthetic seroma and histologic evaluation of the periprosthetic capsule. This diagnosis was verified further by results of immunohistochemical testing, which indicated expression of CD30 and T-cell markers in the periprosthetic seroma only. Our intentions with this case report are to demonstrate that all patients who undergo breast implantation, including transgender women, are at risk of BIA-ALCL and to highlight the importance of cytomorphologic and immunohistochemical screening of seroma fluid in patients with late-onset periprosthetic seroma.

AB - Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare but serious complication in patients with breast implants, Patients are at risk of BIA-ALCL whether they receive breast implants for cosmetic reasons or for reconstructive purposes after surgery for breast cancer or prophylactic mastectomy. During the past decade, an increased number of reports have addressed BIA-ALCL. Herein, we describe BIA-ALCL in a transgender woman. The patient received breast implants as part of her gender transition and was diagnosed with BIA-ALCL 20 years later. The patient underwent several revisional operations in the 20 years after her primary breast surgery to treat unexplained pain with low-grade fever, severe capsular contracture (Baker grade III-IV), and several instances of implant rupture. In July 2016, the patient presented to our office with "late-onset" periprosthetic seroma 5 years after her last revisional breast surgery. She was diagnosed with BIA-ALCL without capsular invasion based on results of cytologic analysis of the periprosthetic seroma and histologic evaluation of the periprosthetic capsule. This diagnosis was verified further by results of immunohistochemical testing, which indicated expression of CD30 and T-cell markers in the periprosthetic seroma only. Our intentions with this case report are to demonstrate that all patients who undergo breast implantation, including transgender women, are at risk of BIA-ALCL and to highlight the importance of cytomorphologic and immunohistochemical screening of seroma fluid in patients with late-onset periprosthetic seroma.

UR - http://www.scopus.com/inward/record.url?scp=85031794324&partnerID=8YFLogxK

U2 - 10.1093/asj/sjx098

DO - 10.1093/asj/sjx098

M3 - Article

VL - 37

SP - NP83-NP87

JO - Aesthetic Surgery Journal

JF - Aesthetic Surgery Journal

SN - 1090-820X

IS - 8

ER -

De Boer M, Van Der Sluis WB, De Boer JP, Overbeek LIH, Van Leeuwen FE, Rakhorst HA et al. Breast implant-associated anaplastic large-cell lymphoma in a transgender woman. Aesthetic Surgery Journal. 2017 Sep 1;37(8):NP83-NP87. https://doi.org/10.1093/asj/sjx098